UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
This article was originally published in The Pink Sheet Daily
Executive Summary
British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.